📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 14:09
8 analysed today
FollowTelegram
8
Today
149,959
All-time analysed
42,990
Positive
6,669
Negative
91,590
Neutral
8,642
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Q1 Revenue drops 36% YoY to ₹0.83 Cr; Net Profit declines to ₹8.03 Lakhs
Desh Rakshak Aushdhalaya reported a weak start to FY27, with Q1 revenue from operations falling 36.3% YoY to ₹82.83 Lakhs. On a sequential basis, the performance saw a sharp contraction of 76% compared to the ₹3.45 Cr revenue reported in the March 2026 quarter. Net profit for the quarter stood at ₹8.03 Lakhs, down 16.3% from ₹9.59 Lakhs in the same period last year. The company remains a micro-cap entity with high volatility in its quarterly financial performance.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing a significant contraction in both revenue and profitability compared to both the previous year and the preceding quarter.
Why it mattersFor a company with annual revenues of only ~₹7 Cr, a 36% YoY drop in quarterly revenue is material and suggests challenges in maintaining sales momentum or distribution reach.
Revenue (Q1 FY27): ₹82.83 LakhsRevenue Growth (YoY): -36.3%Net Profit (Q1 FY27): ₹8.03 LakhsQ1 Revenue vs TTM Revenue: ~11.8%EPS (Q1 FY27): ₹0.14
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the sharp decline in top-line and bottom-line performance.
📈 Long termLimited structural significance unless the company can demonstrate a path to scaling its Ayurvedic medicine business beyond its current small revenue base.
⚠ Risk flags
- Significant sequential revenue volatility
- Micro-cap liquidity risk
- High client/market concentration in a single segment (Ayurvedic Medicines)
Key Highlights
Revenue from operations decreased to ₹82.83 Lakhs from ₹129.99 Lakhs in the year-ago quarter.
Net profit for the quarter ended June 30, 2026, fell to ₹8.03 Lakhs vs ₹9.59 Lakhs YoY.
Earnings Per Share (EPS) declined to ₹0.14 from ₹0.22 in the corresponding quarter of the previous year.
Total expenses were contained at ₹74.80 Lakhs, down from ₹120.40 Lakhs YoY, primarily due to lower material consumption costs of ₹8.22 Lakhs.
The company previously raised ₹2.77 Cr through a preferential allotment of 12,60,000 shares in September 2025.
👀 What to Watch
Investors should monitor whether the sharp sequential revenue drop (76% vs Q4 FY26) is a seasonal trend or a structural decline in demand for its Ayurvedic products. Given the micro-cap nature (₹14 Cr market cap), liquidity and earnings volatility remain high risks.
Rs 8.03 Lakhs Q1 PAT; Revenue drops 36% YoY to Rs 82.83 Lakhs
Desh Rakshak Aushdhalaya reported a weak set of results for Q1 FY27, with revenue from operations falling 36.3% YoY to Rs 82.83 Lakhs from Rs 129.99 Lakhs. Net profit followed suit, declining to Rs 8.03 Lakhs compared to Rs 9.59 Lakhs in the same quarter last year. The sequential performance was even more concerning, with revenue dropping 76% from the Rs 345.33 Lakhs reported in the March 2026 quarter. The company also confirmed a change in its Registrar and Share Transfer Agent (RTA) to Nivis Corpserve LLP.
Confidence: HIGH
What changedThe company reported its first-quarter financial results for FY27 and formally noted the transition to a new RTA, Nivis Corpserve LLP, effective June 20, 2026.
Why it mattersFor a micro-cap company with a Rs 14 Cr market cap, a significant drop in quarterly revenue and profitability can severely impact liquidity and valuation multiples. The sharp decline suggests potential seasonal or operational challenges in the Ayurvedic medicine segment.
Q1 Revenue: Rs 82.83 LakhsQ1 PAT: Rs 8.03 LakhsYoY Revenue Growth: -36.3%QoQ Revenue Growth: -76.1%Preferential Issue Value: Rs 2.77 Cr
📅 Short termThe stock may face downward pressure in the short term due to the significant decline in both YoY and QoQ financial performance.
📈 Long termLimited structural significance unless the company can demonstrate consistent revenue growth and scale its Ayurvedic product portfolio beyond its current small base.
⚠ Risk flags
- High quarterly revenue volatility
- Significant sequential earnings decline
- Micro-cap liquidity risk
- Concentrated business segment (Ayurvedic medicines only)
Key Highlights
Revenue from operations declined 36.3% YoY to Rs 82.83 Lakhs in Q1 FY27.
Net profit for the quarter stood at Rs 8.03 Lakhs, down from Rs 9.59 Lakhs in Q1 FY26.
Total expenses were reduced to Rs 74.80 Lakhs from Rs 120.40 Lakhs YoY, primarily due to lower material costs.
Basic and Diluted EPS decreased to Rs 0.14 from Rs 0.22 in the year-ago period.
The company raised Rs 2.77 Cr through a preferential allotment of 12,60,000 shares at Rs 22 each in late 2025.
👀 What to Watch
Investors should monitor the company's ability to stabilize its top-line, as the sharp sequential revenue drop (76% QoQ) indicates high business volatility. Watch for updates on how the Rs 2.77 Cr raised via preferential allotment is being deployed to drive growth.
